| CHD |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$0.91 vs. cons $0.90 |
MEDIUM |
| CHD |
Report |
Organic sales growth (Q2 2026) |
BEAT |
pred ~3.3% vs. cons 3.0% |
MEDIUM |
| CHD |
Report |
Adjusted gross-margin expansion (Q2 2026) |
BEAT |
pred ~60 bps vs. cons 50 bps |
MEDIUM |
| CHD |
Guide |
Adjusted EPS (FY 2026 midpoint) |
BETTER |
guide ~$3.76 vs. cons $3.74 (FY 2026) |
MEDIUM |
| CHD |
Guide |
Organic sales growth (FY 2026 midpoint) |
UNCHANGED |
guide ~3.5% vs. cons 3.5% (FY 2026) |
HIGH |
| CHD |
Guide |
Adjusted gross-margin expansion (FY 2026) |
UNCHANGED |
guide ~100 bps vs. cons 100 bps (FY 2026) |
MEDIUM |
| CHD |
Guide |
Adjusted EPS (Q3 2026) |
LOWER |
guide ~$0.91 vs. cons $0.92 (Q3 2026) |
MEDIUM |
| CHD |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.8% |
— |
MEDIUM |
| CHD |
Return |
5-day cumulative residual |
+0.2% (FADE) |
Day-1 residual ~+0.8% vs. five-day cumulative residual ~+0.2%: modest Q2 beats support the initial move, but unchanged full-year guidance and a Q3 EPS guide about $0.01 below consensus limit estimate revisions and cause most of the gain to fade. |
MEDIUM |